Published in Neuro Oncol on February 11, 2010
Death receptors as targets in cancer. Br J Pharmacol (2013) 1.24
Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biol Ther (2011) 1.02
Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors. Oncogene (2012) 0.95
Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. PLoS One (2013) 0.91
Clinically applicable human adipose tissue-derived mesenchymal stem cells delivering therapeutic genes to brainstem gliomas. Cancer Gene Ther (2015) 0.84
Radiation-induced tumor neoantigens: imaging and therapeutic implications. Am J Cancer Res (2011) 0.84
Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance. Am J Clin Exp Immunol (2013) 0.84
TNFRSF10B polymorphisms and haplotypes associated with increased risk of death in non-small cell lung cancer. Carcinogenesis (2013) 0.78
Inhibition of Notch1 signaling overcomes resistance to the death ligand Trail by specificity protein 1-dependent upregulation of death receptor 5. Cell Death Dis (2015) 0.77
TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2. Sci Rep (2015) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
Mitochondria and apoptosis. Science (1998) 23.41
Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity (1995) 10.59
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med (1999) 9.78
Inhibition of death receptor signals by cellular FLIP. Nature (1997) 9.58
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (1997) 6.82
The receptor for the cytotoxic ligand TRAIL. Science (1997) 6.39
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem (1996) 6.22
An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science (1997) 6.10
Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer (2002) 4.76
The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer (2008) 4.42
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem (1998) 3.88
Induction of apoptosis by cancer chemotherapy. Exp Cell Res (2000) 3.51
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol (2007) 3.37
The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity (1997) 3.11
A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res (1996) 3.00
Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem (2001) 2.94
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med (2001) 2.87
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev (2003) 2.84
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med (2001) 2.66
A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol (1997) 2.31
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ (2004) 2.17
Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene (1998) 1.98
Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene (2002) 1.97
Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol (2004) 1.90
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem (2004) 1.88
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res (2007) 1.87
Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res (2000) 1.81
Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med (2004) 1.73
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer (2005) 1.58
mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol (2005) 1.56
Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem (2002) 1.54
Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest (2004) 1.52
The caspase-8 modulator c-FLIP. Crit Rev Immunol (2005) 1.52
Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol (2001) 1.46
Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther (2006) 1.45
A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res (2008) 1.44
Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene (2006) 1.37
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci U S A (2008) 1.33
Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J Immunol (2003) 1.33
APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett (1998) 1.32
Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery (2007) 1.27
On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol (2007) 1.27
Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res (2004) 1.26
Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res (2002) 1.21
Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene (2003) 1.16
Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol (2003) 1.14
Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. J Neurosci (2006) 1.11
Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res (2005) 1.09
Monoclonal antibody therapy for solid tumors. Cancer Treat Rev (2000) 1.09
Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg (2001) 1.09
Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ (2004) 1.05
Calcium/calmodulin-dependent protein kinase II regulation of c-FLIP expression and phosphorylation in modulation of Fas-mediated signaling in malignant glioma cells. J Biol Chem (2002) 1.01
Expression of TRAIL and its receptors in human brain tumors. Biochem Biophys Res Commun (1999) 1.00
Avoiding premature apoptosis of normal epidermal cells. Nat Med (2001) 0.97
Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL. Mol Cancer Ther (2006) 0.96
Effect of NF-kappaB, survivin, Bcl-2 and Caspase3 on apoptosis of gastric cancer cells induced by tumor necrosis factor related apoptosis inducing ligand. World J Gastroenterol (2004) 0.95
CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene (2001) 0.94
Apoptosis: molecular mechanisms and implications for cancer chemotherapy. Pharm World Sci (1997) 0.91
Loss of caspase-8 expression in neuroblastoma is related to malignancy and resistance to TRAIL-induced apoptosis. Med Pediatr Oncol (2000) 0.91
Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand. Cell Physiol Biochem (2007) 0.91
Monoclonal antibody drug conjugates in the treatment of cancer. Curr Opin Immunol (1999) 0.90
Radiation and the Apo2L/TRAIL apoptotic pathway preferentially inhibit the colonization of premalignant human breast cells overexpressing cyclin D1. Cancer Res (2000) 0.85
Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor-related apoptosis-inducing ligand. J Neurosurg (2007) 0.82
Expression of O6-methylguanine-DNA methyltransferase and chloroethylnitrosourea resistance of human brain tumors. Jpn J Clin Oncol (1992) 0.78
Influence of spinal cord compression and traumatic force on the severity of cervical spinal cord injury associated with ossification of the posterior longitudinal ligament. Spine (Phila Pa 1976) (2014) 1.98
Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register. Stroke (2009) 1.63
A randomized controlled trial of hydrocortisone against hyponatremia in patients with aneurysmal subarachnoid hemorrhage. Stroke (2007) 1.58
Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc Natl Acad Sci U S A (2006) 1.45
Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society. J Stroke Cerebrovasc Dis (2013) 1.40
Relative systolic blood pressure reduction and clinical outcomes in hyperacute intracerebral hemorrhage: the SAMURAI-ICH observational study. J Hypertens (2015) 1.40
Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. Clin Cancer Res (2008) 1.35
Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization. Microvasc Res (2008) 1.22
HIV latency in the humanized BLT mouse. J Virol (2011) 1.19
Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers. Int J Oncol (2009) 1.17
Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells. Neurosurgery (2008) 1.14
Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood (2012) 1.11
Reduced estimated glomerular filtration rate is associated with stroke outcome after intravenous rt-PA: the Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement (SAMURAI) rt-PA registry. Cerebrovasc Dis (2010) 1.11
Lecithinized superoxide dismutase improves outcomes and attenuates focal cerebral ischemic injury via antiapoptotic mechanisms in rats. Stroke (2007) 1.10
Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res (2005) 1.09
Extradural anterior clinoidectomy. Technical note. J Neurosurg (2005) 1.04
Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248. Mol Cancer Ther (2008) 1.03
Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice. PLoS One (2012) 1.01
Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Jpn J Clin Oncol (2007) 1.01
Engineering of sugar metabolism of Corynebacterium glutamicum for production of amino acid L-alanine under oxygen deprivation. Appl Microbiol Biotechnol (2010) 1.01
Meningeal melanocytoma associated with ipsilateral nevus of Ota presenting as intracerebral hemorrhage: case report. Neurosurgery (2005) 1.01
Choroid plexus papilloma of the third ventricle in the fetus. Case illustration. J Neurosurg (2004) 1.00
Clinical relationship between cervical spinal canal stenosis and traumatic cervical spinal cord injury without major fracture or dislocation. Eur Spine J (2013) 1.00
Stem cell-based anti-HIV gene therapy. Virology (2011) 0.94
Impact of early blood pressure variability on stroke outcomes after thrombolysis: the SAMURAI rt-PA Registry. Stroke (2013) 0.92
Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats. J Immunol (2008) 0.91
The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: assessment of receptor contribution. Int J Oncol (2008) 0.90
Efficient antibody production upon suppression of O mannosylation in the yeast Ogataea minuta. Appl Environ Microbiol (2007) 0.89
Angiogenesis in atherosclerotic plaque obtained from carotid endarterectomy: association between symptomatology and plaque morphology. Neurol Med Chir (Tokyo) (2010) 0.88
Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist. Pharmacol Biochem Behav (2010) 0.87
Soft-tissue damage and segmental instability in adult patients with cervical spinal cord injury without major bone injury. Spine (Phila Pa 1976) (2012) 0.87
[Cranioplasty using the patient's autogenous bone preserved by freezing--an examination of post-operative infection rates]. No Shinkei Geka (2002) 0.86
Radiosurgery for cerebral arteriovenous malformation during pregnancy: A case report focusing on fetal exposure to radiation. Asian J Neurosurg (2010) 0.86
Regional expression of Fos-like immunoreactivity following seizures in Noda epileptic rat (NER). Epilepsy Res (2009) 0.85
Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status. J Neurooncol (2008) 0.84
Anti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells. PLoS One (2012) 0.83
Therapeutic potential of alpha2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders. Neurosci Lett (2009) 0.83
Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.82
Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor-related apoptosis-inducing ligand. J Neurosurg (2007) 0.82
Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry. Cerebrovasc Dis (2012) 0.82
Conjugate eye deviation in acute intracerebral hemorrhage: stroke acute management with urgent risk-factor assessment and improvement--ICH (SAMURAI-ICH) study. Stroke (2012) 0.82
Antibody expression in protease-deficient strains of the methylotrophic yeast Ogataea minuta. FEMS Yeast Res (2007) 0.81
Nationwide survey of antihypertensive treatment for acute intracerebral hemorrhage in Japan. Hypertens Res (2009) 0.81
Scn1a missense mutation causes limbic hyperexcitability and vulnerability to experimental febrile seizures. Neurobiol Dis (2010) 0.81
Acute carotid arterial occlusion after burr hole surgery for chronic subdural haematoma in moyamoya disease. J Clin Neurosci (2004) 0.81
Efficient induction of HIV-1 replication in latently infected cells through contact with CD4+ T cells: involvement of NF-kappaB activation. Virology (2007) 0.81
Region-specific elevation of D₁ receptor-mediated neurotransmission in the nucleus accumbens of SHR, a rat model of attention deficit/hyperactivity disorder. Neuropharmacology (2012) 0.81
Edaravone, a free radical scavenger, attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia. Neurol Res (2013) 0.81
Pathophysiological roles of serotonergic system in regulating extrapyramidal motor functions. Biol Pharm Bull (2013) 0.80
Radiation-induced apoptosis of oligodendrocytes in the adult rat optic chiasm. Neurol Res (2005) 0.80
Expressional analysis of inwardly rectifying Kir4.1 channels in Noda epileptic rat (NER). Brain Res (2013) 0.80
Postoperative assessment of extracranial-intracranial bypass by time-resolved 3D contrast-enhanced MR angiography using parallel imaging. AJNR Am J Neuroradiol (2005) 0.79
Analysis of the risk factors for severity of neurologic status in 216 patients with thoracolumbar and lumbar burst fractures. Spine (Phila Pa 1976) (2011) 0.79
Switching constant domains enhances agonist activities of antibodies to a thrombopoietin receptor. Nat Biotechnol (2007) 0.79
Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens. Neuropharmacology (2008) 0.79
Expressional analysis of the astrocytic Kir4.1 channel in a pilocarpine-induced temporal lobe epilepsy model. Front Cell Neurosci (2013) 0.79
Visualization of extracranial-intracranial bypass using multidetector-row helical computed tomography angiography. J Comput Assist Tomogr (2003) 0.78
Analysis of the risk factors for tracheostomy in traumatic cervical spinal cord injury. Spine (Phila Pa 1976) (2012) 0.78
Effects of tandospirone, a 5-HT1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice. J Pharmacol Sci (2009) 0.78
A novel HIV-1 reporter virus with a membrane-bound Gaussia princeps luciferase. J Virol Methods (2012) 0.78
Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report. Int J Clin Oncol (2013) 0.78
Nationwide survey of neuro-specialists' opinions on anticoagulant therapy after intracerebral hemorrhage in patients with atrial fibrillation. J Neurol Sci (2011) 0.78
Preferential suppression of limbic Fos expression by intermittent hypoxia in obese diabetic mice. Neurosci Res (2013) 0.77
Delineation of the safe zone in surgery of sylvian insular triangle: morphometric analysis and magnetic resonance imaging study. Neurosurgery (2012) 0.77
Stroke outcomes of Japanese patients with major cerebral artery occlusion in the post-alteplase, pre-MERCI era. J Stroke Cerebrovasc Dis (2012) 0.77
[Clinical significance of natriuretic peptides in patients with aneurysmal subarachnoid hemorrhage]. No To Shinkei (2003) 0.77
NIHSS-time score easily predicts outcomes in rt-PA patients: the SAMURAI rt-PA registry. J Neurol Sci (2013) 0.76
CHADS2 score is associated with 3-month clinical outcomes after intravenous rt-PA therapy in stroke patients with atrial fibrillation: SAMURAI rt-PA Registry. J Neurol Sci (2011) 0.76
Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test. Prog Neuropsychopharmacol Biol Psychiatry (2008) 0.76
Intravenous alteplase at 0.6 mg/kg for acute stroke patients with basilar artery occlusion: the stroke acute management with urgent risk factor assessment and improvement (SAMURAI) Recombinant tissue plasminogen activator registry. J Stroke Cerebrovasc Dis (2012) 0.76
Effect of serum lipid levels on stroke outcome after rt-PA therapy: SAMURAI rt-PA registry. Cerebrovasc Dis (2012) 0.76
One-stage clipping of bilateral middle cerebral artery aneurysms via the bilateral pterional keyhole approach. Neurol Med Chir (Tokyo) (2013) 0.76
Does Reducing the Duration from Symptom Onset to Recanalization Improve the Results of Intracranial Mechanical Thrombectomy in the Elderly? Neurol Med Chir (Tokyo) (2017) 0.75
Involvement of aspartoacylase in tremor expression in rats. Exp Anim (2016) 0.75
New aneurysm clip system. Neurosurgery (2010) 0.75
Neuro-oncology: continuing multidisciplinary progress. Lancet Neurol (2011) 0.75
Higher serum pentosidine, an advanced glycation end product, in branch atheromatous disease among small vessels occlusion. J Neurosurg Sci (2016) 0.75
Serum pentosidine, an advanced glycation end product, indicates poor outcomes after acute ischemic stroke. J Stroke Cerebrovasc Dis (2010) 0.75
Severe progressive sensorineural hearing loss improved after removal of large jugular foramen schwannoma. Auris Nasus Larynx (2010) 0.75
[Microanatomy of the temporal bone]. No Shinkei Geka (2005) 0.75
Escalation regimen of cilostazol for acute brain infarction. Intern Med (2011) 0.75
Synthesis and structure-activity relationships of thioflavone derivatives as specific inhibitors of the ERK-MAP kinase signaling pathway. Bioorg Med Chem (2004) 0.75
[Cryptogenic stroke--vascular malformation-clinical features]. No To Shinkei (2006) 0.75
Fully human antibody exhibits pan-human leukocyte antigen-DR recognition and high in vitro/vivo efficacy against human leukocyte antigen-DR-positive lymphomas. Cancer Sci (2007) 0.75
[Effects of statin use on intracranial hemorrhage and clinical outcome after intravenous rt-PA for acute ischemic stroke: SAMURAI rt-PA registry]. Rinsho Shinkeigaku (2010) 0.75
Hyperglycemia and hemorrhagic transformation of cerebral infarction: a macroscopic hemorrhagic transformation rat model. Acta Neurochir Suppl (2011) 0.75
[Dural arteriovenous malformation, dural arteriovenous fistula]. No To Shinkei (2005) 0.75
[Surgical anatomy for orbitozygomatic approach]. No Shinkei Geka (2010) 0.75